Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

Illumina reported after the close of the market on Thursday that its fourth quarter 2021 revenues rose 26 percent year over year, narrowly beating its own forecast last month of 25 percent growth.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced financial results for the fourth quarter and year ended December 31, 2021.

Jiangsu Mole Bioscience obtained the approval of the Helicobacter pylori 23S rRNA gene and gyrA gene mutation test kit (fluorescence PCR method) by NMPA. This kit is the first product in China that can simultaneously detect clarithromycin and levofloxacin resistance genes.

Roche on Thursday reported a 29 percent year-over-year increase in sales in its diagnostics division for full-year 2021, driven by momentum in the base business and continued demand for COVID-19 testing.

Eurofins Scientific said on Wednesday that its subsidiary Eurofins Clinical Testing Lux Sarl has acquired Vietnamese genetic testing firm Genetic Testing Service JSC (Gentis).

On February 7, the U.S. Commerce Department said that it had added 33 Chinese entities to its so-called 'unverified list', which requires U.S. exporters to go through more procedures before shipping goods to the entities.

Qiagen reported after the close of the market on Tuesday that its fourth quarter revenues grew 2 percent year over year, beating previous guidance and analyst estimates on the top and bottom line.

DNA sequencing firm Element Biosciences said on Tuesday that it has acquired Loop Genomics for an undisclosed amount.

On January 29, Shenzhen Tisenc Medical Devices Co., Ltd. underwent an industrial and commercial change. All the original shareholders withdrew, and WONDFO BIOTECH (300482) was newly added, holding 100% of the shares.

Hologic reported after the close of the market on Wednesday that revenues for its first quarter of fiscal year 2022 decreased 9 percent year over year, driven by lower sales of COVID-19 assays.